Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
The modified Medical Research Council (mMRC) dyspnea scale is a simple functional breathlessness measure used in COPD and other chronic respiratory diseases. It grades dyspnea from 0 (only with strenuous exercise) to 4 (too breathless to leave home or breathless while dressing).
Formula: mMRC grade is selected directly from 0 to 4 based on functional dyspnea description.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The mMRC Dyspnea Scale measures chronic, stable breathlessness on exertion. It must be assessed when the patient is at their usual functional level — not during an acute exacerbation, hospitalization, or within 4–6 weeks of an exacerbation when function is still recovering. Ask: 'On a normal day for you, which of these descriptions best fits your breathlessness?'
Read the five grade descriptions to the patient and ask them to choose the one that best matches their typical breathlessness: Grade 0 = breathless only with strenuous exercise; Grade 1 = breathless when hurrying on level ground or walking up a slight hill; Grade 2 = walks slower than most people of the same age on level ground because of breathlessness, or has to stop for breath when walking at own pace; Grade 3 = stops for breath after walking about 100 meters or after a few minutes on level ground; Grade 4 = too breathless to leave the house, or breathless when dressing or undressing.
mMRC ≥2 = high symptom burden threshold for GOLD Group B or E classification (only one of mMRC ≥2 or CAT ≥10 needs to be met). mMRC is one of four BODE index components (score 0–3 for dyspnea domain: Grade 0–1 = 0 points, Grade 2 = 1 point, Grade 3 = 2 points, Grade 4 = 3 points). mMRC ≥2 is also a threshold for lung transplant referral consideration in COPD alongside BODE ≥5.
Pulmonologists & General Practitioners
mMRC is one of the two validated symptom tools (alongside CAT) used to classify COPD patients into GOLD ABE groups. mMRC ≥2 defines high symptom burden qualifying for Group B or E status, which determines initial bronchodilator therapy selection. Because mMRC is a single-question scale requiring less than 1 minute, it is easily integrated into every COPD follow-up visit as part of routine symptom monitoring.
ILD & Pulmonary Hypertension Specialists
mMRC dyspnea grade is used to track disease progression in idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, and pulmonary arterial hypertension. A worsening mMRC grade over 3–6 months signals significant functional decline, supports listing urgency for lung transplant evaluation, and triggers consideration of anti-fibrotic therapy dose adjustment or advanced therapies.
COPD Specialists & Researchers
mMRC is the dyspnea domain (D) of the BODE index — the most validated COPD prognostic score. mMRC contributes 0–3 points to the BODE total (0–10). Serial BODE calculation including mMRC tracks disease trajectory over time; a BODE decrease of ≥1 point after pulmonary rehabilitation is associated with 12% reduced all-cause mortality (Cote & Celli, NEJM 2007).
Transplant Pulmonology Teams
mMRC ≥2 in COPD, combined with BODE ≥5 or progressive disease, meets ISHLT 2023 lung transplant referral criteria. mMRC ≥4 (unable to leave the house or breathless when dressing) with GOLD 4 indicates end-stage COPD warranting urgent transplant evaluation. Tracking mMRC trajectory over 6–12 months helps identify patients with accelerating functional decline who need early transplant listing.
Clinical Researchers
mMRC is used as a secondary endpoint in COPD pharmacotherapy and pulmonary rehabilitation trials. It is simple, reproducible, and widely understood. The inter-rater reliability (κ=0.83) makes it suitable for multicenter studies. mMRC change from baseline is a standard secondary outcome in trials of bronchodilators, ICS, and pulmonary rehabilitation programs.
mMRC is a single-dimension scale measuring only breathlessness limitation. The COPD Assessment Test (CAT) is an 8-item questionnaire also capturing cough, sputum, chest tightness, activity limitation, confidence, sleep, and energy. For comprehensive COPD symptom assessment, CAT provides more information. GOLD allows either mMRC ≥2 or CAT ≥10 to qualify as high-symptom burden — either alone is sufficient for Group B/E classification.
In GOLD ABE grouping: mMRC 0–1 = low symptom burden (Group A if low exacerbations); mMRC ≥2 = high symptom burden (Group B if low exacerbations, Group E if ≥2 exacerbations or ≥1 hospitalization). This threshold mirrors the real-world functional impact: mMRC Grade 2 (walks slower than peers) represents a meaningful daily life limitation. Importantly, only one criterion (mMRC ≥2 OR CAT ≥10) needs to be met for high-symptom classification.
In the BODE index, mMRC grades are converted to points: mMRC 0–1 = 0 BODE points; mMRC 2 = 1 point; mMRC 3 = 2 points; mMRC 4 = 3 points. Combined with FEV1 (0–3 points), 6MWD (0–3 points), and BMI (0–1 point), the total BODE score predicts 52-month mortality from 19% (BODE 0–2) to 80% (BODE 7–10). Accurately scoring mMRC is essential for reliable BODE calculation.
Nishimura et al. (AJRCCM 2002) demonstrated that mMRC dyspnea grade is an independent predictor of 5-year mortality in COPD, with significantly worse survival for mMRC ≥3 after adjusting for FEV1. This makes mMRC one of the simplest available prognostic tools — more information is gathered from a 30-second question than from many complex scores.
Patients with COPD frequently reduce their activity level over time, leading to underreporting of dyspnea on standard activity-based questions. A patient who has stopped going upstairs entirely may answer 'Grade 1' because they are only breathless on hills — but only because they have avoided hills. Ask specifically: 'Are there activities you've stopped doing because of shortness of breath?' This reveals the true functional impact that the mMRC grades may underestimate.
A 1-grade increase in mMRC over 6–12 months in a stable COPD patient represents clinically meaningful deterioration requiring investigation: (1) Rule out exacerbation or new comorbidity (heart failure, anemia, pulmonary embolism); (2) Review bronchodilator adherence and technique; (3) Consider dual bronchodilator if on monotherapy; (4) Calculate BODE index to reassess prognosis; (5) Refer for pulmonary rehabilitation if not already enrolled.
The mMRC scale has excellent test-retest reliability (κ=0.83 in outpatient COPD settings, Bestall et al.) and takes less than 60 seconds to administer. This makes it ideal for serial monitoring at every clinic visit. The time investment is minimal relative to the prognostic and management information gained. Document mMRC grade at every COPD visit in the same way vital signs are recorded.
Unlike the Borg scale (used during exercise testing) or acute dyspnea scores, mMRC measures chronic, stable breathlessness on exertion. It does not change rapidly with bronchodilators (unlike FEV1) and should not be used to assess acute bronchodilator response in the clinic. mMRC changes occur over weeks to months as underlying disease severity or fitness level changes. For acute dyspnea assessment, use VAS or modified Borg scale.
mMRC is specifically validated for COPD and chronic respiratory diseases. For pulmonary arterial hypertension (PAH), the WHO Functional Class (WHO-FC I–IV) and NYHA classification are preferred. While mMRC and WHO-FC describe similar functional limitation concepts, they are calibrated for different patient populations. In patients with combined cardiopulmonary disease, document both mMRC (pulmonary) and NYHA (cardiac) assessments for complete functional classification.
Modified MRC Dyspnea Scale (Mahler & Wells, Clin Chest Med 1988) adapted from the original MRC scale (Fletcher et al., BMJ 1959). BODE index validation using mMRC: Celli et al. (NEJM 2004). mMRC as independent 5-year mortality predictor: Nishimura et al. (AJRCCM 2002). GOLD 2024 threshold: mMRC ≥2 defines high-symptom burden (Group B/E). Correlation with 6MWD r=−0.71: Bestall et al. (Thorax 1999). Inter-rater reliability κ=0.83 in outpatient COPD settings.
Higher mMRC grades reflect greater functional limitation from breathlessness and usually support closer symptom-directed management.
Use this scale during baseline and follow-up respiratory assessments, especially in COPD symptom evaluation.
mMRC is a single-domain symptom scale and does not capture all dimensions of respiratory disease severity or exacerbation risk.
For related assessments, see COPD GOLD, ACT Score and Pack-Year Calculator.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Classify COPD severity using 2024 GOLD spirometric stages (GOLD 1–4) and ABE exacerbation grouping. Guides inhaler step-up therapy, pulmonary rehabilitation, and oxygen therapy decisions.
OpenPulmonologyCalculate the Asthma Control Test score to assess asthma control over the past 4 weeks.
OpenPulmonologyCalculate pack-years from cigarettes per day and years smoked. Useful for documenting smoking burden and lung cancer screening discussions.
Open